Compare Herbalife Nutrition Ltd (HLF) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Twist Bioscience Corp — how do they compare? Herbalife Nutrition Ltd trades at $12.86 (market cap $1.34B), while Twist Bioscience Corp trades at $162.65 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 7.5× Herbalife Nutrition Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Twist Bioscience Corp for 27 Days on average.
| HLF | TWST | |
|---|---|---|
Market Cap | $1.34B | $10.08B |
Volume | 1,589,457 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $205.00 |
52-Week Low | $7.75 | $25.45 |
Typical Hold Time | 43 Days | 27 Days |
Enterprise Value | $3.18B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.65, up 0.56% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.22 and P/S of 0.26. Recent earnings were mixed, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company announced a $250 million share repurchase program and a CEO transition effective October 31, 2026. Cash flow trends show improvement, with 2026 projected net cash flow turning positive at $50 million.
The outlook is cautiously optimistic, supported by analyst consensus price target of $19.00 implying significant upside. Key opportunities include debt reduction progress and margin expansion plans. Risks include inconsistent earnings performance, high debt levels, and investor scrutiny following the CEO transition. The stock remains a value play if execution improves.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
